• Molbio Diagnostics Ltd Ipo
78994
Off
molbio

Molbio Diagnostics IPO

  • Status: Live
  • RHP:
  • BSE NSE
  • ₹ 13,824 / 18 shares

    Minimum Investment

Molbio Diagnostics IPO Details

  • Open Date

    10 Aug 2026

  • Close Date

    12 Aug 2026

  • IPO Price Range

    ₹ 768 to ₹807

  • IPO Size

    ₹ 939.70 Cr

Apply for Molbio Diagnostics IPO

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Financials SWOT FAQ Contacts

Molbio Diagnostics IPO Timeline

Molbio Diagnostics IPO Subscription Status

Last Updated: 11 August 2026 5:36 PM by 5paisa

Molbio Diagnostics Limited is a global point-of-care molecular diagnostics company specialising in the development, manufacture and commercialisation of rapid diagnostic solutions. Its proprietary battery-operated Truenat PCR platform delivers accurate results within an hour, even in resource-constrained settings. The company offers diagnostic assays for more than 30 diseases, operates six manufacturing facilities in India, serves customers across 90+ countries, and continues to strengthen its portfolio through innovation, strategic collaborations and acquisitions. 

Established in: 2000 

Managing Director: Vajapeyam Krishna Prasad

Molbio Diagnostics Objectives

1. Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.     

2. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and     

3. General Corporate Purposes

Molbio Diagnostics IPO Size

Types Size
Total IPO Size ₹939.70 Cr 
Offer For Sale ₹739.70 Cr 
Fresh Issue ₹200.00 Cr 

Molbio Diagnostics IPO Lot Size

Application Lots Shares Amount (₹)
Individual investors (IND) (Min)  1 18  ₹13,824 
Individual investors (IND) (Max)  13 234  ₹1,80,838 
S - HNI (Min)  14 252  ₹1,93,536 
S - HNI (Max)  68 1,224  ₹9,97,050 
B - HNI (Min)  69 1,242  ₹9,53,856 

Molbio Diagnostics IPO Reservation

Investors Category Subscription (times) Shares Offered* Shares bid for Total Amount (Cr.)*
QIB (Ex Anchor) 1.39     23,25,146 32,34,672 261.038
Non-Institutional Buyers 4.46     17,43,859 77,84,946     628.245
  bNII 4.31 11,62,573 50,08,518 404.187
 sNII 7.02 5,81,286 40,78,548 329.139
Individual Investors (IND category bidding for 2 Lots) 3.19 40,69,004 1,29,84,534 1,047.852
Total** 2.95 81,58,529 2,41,02,360 1,945.060

*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.

Profit and Loss

Balance Sheet

Particulars (In ₹ Crores) FY24 FY25 FY26
Revenue 836.56  1020.42  1445.69 
EBITDA 185.09  256.64  328.24 
PAT 83.54  138.58  164.14 
Particulars (In ₹ Crores) FY24 FY25 FY26
Total Assets 1221.06  1461.56  2148.24 
Share Capital 2.25  2.26  11.28 
Total Liabilities 392.22  494.27  839.652 
Cash Flows (₹ Crores) FY24 FY25 FY26
Net Cash Generated From / (used in) Operating Activities 9.57  287.10  50.39 
Net Cash Generated From / (used in) Investing Activities -45.01  -122.65  -93.22 
Net Cash Generated From / (used in) Financing Activities -31.55  -26.15  -276.07
Net Increase (Decrease) in Cash and Cash Equivalents 66.99  138.30  233.23 


Strengths

1. Proprietary Truenat platform enables rapid, accurate molecular diagnostics.  

2. Strong portfolio covering over 30 disease-specific diagnostic assays.  

3. Extensive global presence across more than 90 countries.  

4. Robust in-house research supports continuous product innovation. 

Weaknesses

1. Significant reliance on government healthcare procurement programmes.  

2. Revenue vulnerable to fluctuating pandemic-related testing demand.  

3. High research expenditure may pressure operating profitability.  

4. Limited diversification beyond molecular diagnostics core business. 

Opportunities

1. Rising demand for decentralised point-of-care diagnostic solutions.  

2. Expansion into emerging markets with underserved healthcare infrastructure.  

3. Growing non-communicable disease testing broadens addressable market opportunities.  

4. Strategic acquisitions can strengthen technology and product portfolio. 

Threats

1. Intense competition from established global diagnostics manufacturers.  

2. Regulatory changes may delay product approvals and launches.  

3. Pricing pressure from government tenders affects profit margins.  

4. Rapid technological advancements could accelerate product obsolescence.

1. Proprietary Truenat platform offers strong competitive technological advantage. 

2. Expanding global footprint supports long-term revenue growth potential. 

3. Diversified disease portfolio reduces dependence on single diagnostics segment. 

4. Strong innovation pipeline backed by sustained research investments.

The global molecular diagnostics market is expanding rapidly, driven by increasing demand for early disease detection, decentralised healthcare and technological advancements. In India, favourable government initiatives, rising healthcare expenditure and growing awareness of infectious and chronic diseases are supporting market growth. Point-of-care molecular diagnostics are expected to witness strong adoption, particularly in resource-limited settings, creating significant long-term opportunities for companies with innovative, scalable and cost-effective diagnostic platforms.

Upcoming IPOs

View all IPOs
  • Companies
  • Type
  • Opening On
Upcoming IPO Current IPO Recently Listed IPO Subscription

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

  • Flat brokerage
  • Dedicated platform for F&O
  • 0 account opening charges
  • Trade on charts
  • MTF facility up to 4X leverage
  • 0 Transaction cost on MFs
+91
Resend OTP

By proceeding, you agree to all T&C*

footer_form

FAQs

Molbio Diagnostics opens from August 10, 2025 to August 12, 2026.

The size of Molbio Diagnostics is ₹939.70 Cr. 

The price band of Molbio Diagnostics IPO is fixed at ₹768 to ₹807.

Once the Molbio Diagnostics IPO is officially open, one can simply follow the process to apply for the IPO: 

To apply for Molbio Diagnostics IPO, follow the steps given below: 

● Login to your 5paisa account and select the issue in the current IPO section 

● Enter the number of lots and the price at which you wish to apply for the Molbio Diagnostics IPO 

● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange 

You will receive a mandate notification to block funds in your UPI app.

The minimum lot size of Molbio Diagnostics is of 18 shares and the investment required is ₹13,824. 

The share allotment date of Molbio Diagnostics IPO is August 13, 2026

The Molbio Diagnostics IPO will likely be listed on August 17, 2026. 

Kotak Mahindra Capital Co.Ltd is the book running lead managers for Molbio Diagnostics IPO.

1. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and      

2. General corporate purpose